Publication | Open Access

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

VaccinationMelanomaImmunologyTherapeutic VaccineLong-term Clinical ResponsesImmunotherapeuticsAdvanced Melanoma PatientsDermatologyDendritic Cell BiologyImmunotherapyMedicine